Table 1

Relationship between EGFR mutations and clinical and pathologic features in a subset of patients with adenocarcinoma

VariablesCategoryEGFRP
Mutation (%)Wild-type
N 110(49)114
GenderMale40(36)71<0.001
Female70(62)43
Age≤6451(46)600.3481
> 6459(52)54
Smoking statusNever-smoker (pack years = 0)76(68)36<0.001
Ever-smoker34(31)78
Pack years <2011(55)9
20–5015(27)40
>208(22)29
DifferentiationWell to moderately differentiated89(58)65<0.001
Poorly differentiated21(30)49
StageIA and IB69(50)700.8383
IIA through IV41(48)44
Survival3-year survival rate 86%91%0.9933
KRAS mutationMutated0(0)26<0.001
Wild-type97(57)73
TP53 mutationMutated37(47)420.4634
Wild-type59(52)54
  • There were five BACs in our cohort, of which three harbored EGFR mutations.